Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MODICON 21 vs DEMULEN 1/50-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Prevention of pregnancy
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
Terminal elimination half-life: 12–18 hours; clinical context: steady-state reached after 3–5 days of daily dosing
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Ethinyl estradiol undergoes hepatic CYP3A4-mediated hydroxylation and conjugation; norethindrone is reduced and conjugated in liver.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Renal (80% as metabolites, 20% unchanged); biliary/fecal (minor, <5% total)
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Ethinylestradiol: 97% bound to albumin; Norethindrone: 80% bound to albumin and SHBG
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
Ethinylestradiol: 2–4 L/kg; Norethindrone: 3–5 L/kg; large Vd indicates extensive tissue distribution
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Oral: 40–60% (first-pass metabolism reduces systemic availability)
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
No dose adjustment required for chronic kidney disease. Contraindicated in acute renal failure or severe renal impairment (GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances.
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
Contraindicated in acute hepatic disease, hepatic adenomas, or impaired liver function (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution; monitor liver function.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal minors established; dose same as adults (one tablet daily for 21 days, then 7 days off).
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
Not indicated for use in postmenopausal women. No specific dose adjustments for elderly due to lack of indication; consider increased risk of cardiovascular and thrombotic events in women over 35 who smoke.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day); women >35 years who smoke should not use this product.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Thrombotic disorders (thrombophlebitis, venous thromboembolism, arterial thromboembolism),Cardiovascular disease (e.g., myocardial infarction, stroke) especially in smokers >35,Liver disease (e.g., hepatic adenoma, hepatocellular carcinoma),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions (e.g., retinal thrombosis),Headache/migraine,Bleeding irregularities,Depression
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking and age >35 years
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
No specific food restrictions; however, grapefruit juice may increase estrogen levels slightly (theoretical). Maintain consistent intake of folate-rich foods as oral contraceptives may lower folate levels. Avoid St. John's wort (herbal) as it reduces contraceptive efficacy.
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
Modicon 21 is a combination oral contraceptive. First trimester: Epidemiologic studies have not shown an increased risk of birth defects with inadvertent exposure. Second and third trimesters: Use is not indicated during pregnancy; fetal and neonatal risks include cardiovascular and genitourinary anomalies, though data are limited and confounded by maternal condition.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
Combination hormonal contraceptives reduce milk production and may pass into breast milk. M/P ratio not established. Use in breastfeeding is generally not recommended until breastfeeding is well-established (typically after 6 weeks postpartum).
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
Not applicable as Modicon 21 is contraindicated during pregnancy. No dose adjustment is needed.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
MODICON 21 (norethindrone/ethinyl estradiol) is a monophasic oral contraceptive. Administer starting on day 1 of menstrual period (Sunday start or day 1 start). Breakthrough bleeding is common in first cycles; sustained bleeding warrants evaluation. Missed dose protocol: if one pill is missed, take it ASAP and continue schedule; if two or more missed, use backup contraception for 7 days. Advise against smoking due to increased thrombotic risk, especially in women over 35. Assess for contraindications: history of DVT/PE, migraine with aura, breast cancer, liver disease, uncontrolled hypertension, etc. Drug interactions: rifampin, anticonvulsants (phenytoin, carbamazepine), St. John's wort may reduce efficacy.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
Take one pill daily at the same time each day for 21 days, then 7 days off.,If you miss a pill, follow the missed dose instructions in the package insert.,Use backup contraception (e.g., condoms) if you miss two or more pills.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Report any sudden severe headache, chest pain, leg swelling, or vision changes immediately.,You may experience irregular bleeding, nausea, or breast tenderness initially.,This medication does not protect against sexually transmitted infections.,Check with your doctor before starting any new medications, including herbal supplements.
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MODICON 21 vs DEMULEN 1/50-21, answered by our medical review team.
MODICON 21 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.. DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MODICON 21 and DEMULEN 1/50-21 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MODICON 21 is: One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.. The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MODICON 21 and DEMULEN 1/50-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MODICON 21 is classified as Category C. Modicon 21 is a combination oral contraceptive. First trimester: Epidemiologic studies have not shown an increased risk of birth defects with inadvertent exposure. Second and third. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.